Rizou Tatiana, Perlikos Fotis, Lagiou Maria, Karaglani Makrina, Nikolopoulos Sotirios, Toumpoulis Ioannis, Kroupis Christos
Department of Clinical Biochemistry, Attikon University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
J BUON. 2018 Nov-Dec;23(6):1699-1710.
The purpose of this study was the development of new quantitative methodologies for the general (total) COL11A1 gene and the C transcript (RT-qPCR methods for A and E transcripts have already been developed by our group previously), the quantification of all COL11A1 transcripts and the investigation for the first time of their potential association with histopathological prognostic factors in lung cancer.
Real-time RT-qPCR methodologies with dual hybridization probes were developed on the Light Cycler 1.5 platform (Roche,Germany). All COL11A1 transcripts were measured in 27 cDNA lung tissue specimens in a blinded fashion (8 control and 19 non-small cell lung cancer (NSCLC) tissues with known histopathological data). Statistical analysis was performed with the IBM SPSS program.
The novel real-time RT-qPCR methodologies were appropriately validated. All 19 NSCLC samples were positive for the general COL11A1 transcript (range 11.2-1198.0 copies/μg total RNA, while 5 out of 8 control samples were negative: mean values were also statistically significantly different (p<0.001). In 4 tumor samples (21%), no specific COL11A1 transcript was detected. Transcript C was detected in only 3 tumor samples. Regarding transcripts A and E, 13 out of 19 tumor samples were positive for either one (68%) and 11 for both (58%).
No other statistically significant association of the specific transcripts with histopathological data was observed, most probably due to the limited number of samples. As the number of general COL11A1 transcripts/µg exceeds the sum of A+E+C transcripts in all samples, there is opportunity for discovery and identification of other transcripts as well.
本研究的目的是开发针对COL11A1基因总体(全部)和C转录本的新定量方法(本研究小组先前已开发出针对A和E转录本的逆转录定量聚合酶链反应(RT-qPCR)方法),对所有COL11A1转录本进行定量,并首次研究它们与肺癌组织病理学预后因素的潜在关联。
在Light Cycler 1.5平台(德国罗氏公司)上开发了带有双重杂交探针的实时RT-qPCR方法。以盲法在27个肺组织cDNA标本中检测所有COL11A1转录本(8个对照样本和19个具有已知组织病理学数据的非小细胞肺癌(NSCLC)组织)。使用IBM SPSS程序进行统计分析。
新的实时RT-qPCR方法得到了适当验证。所有19个NSCLC样本的COL11A1转录本总体均呈阳性(范围为11.2 - 1198.0拷贝/μg总RNA),而8个对照样本中有5个为阴性:平均值在统计学上也有显著差异(p<0.001)。在4个肿瘤样本(21%)中,未检测到特定的COL11A1转录本。仅在3个肿瘤样本中检测到转录本C。关于转录本A和E,19个肿瘤样本中有13个(68%)其中之一呈阳性,11个(58%)两者均呈阳性。
未观察到特定转录本与组织病理学数据之间存在其他具有统计学意义的关联,很可能是由于样本数量有限。由于所有样本中COL11A1转录本总体/μg的数量超过了A + E + C转录本的总和,因此也有机会发现和鉴定其他转录本。